CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
50.0%
Unknown
1
50.0%
暂无批准数据
- CytoMed Therapeutics has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre to establish a multi-site Phase I clinical trial investigating allogeneic unmodified gamma delta T cells for no-option cancer patients in Malaysia. - The company's allogeneic approach using donor-derived gamma delta T cells offers significant cost advantages over autologous therapies, with faster logistics and broader patient accessibility without triggering immune rejection. - Recent collaborative research with MD Anderson Cancer Center published in September 2025 demonstrated promising potential for CytoMed's CTM-GDT therapy in treating acute myeloid leukemia. - This Malaysian trial complements CytoMed's ongoing Phase I CAR-T clinical trial at National University Hospital Singapore, which targets multiple cancer types including colorectal cancer, lymphoma, and hepatocellular carcinoma.
- CytoMed Therapeutics published preclinical study results demonstrating the promising potential of its allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia in collaboration with MD Anderson Cancer Center. - The research provides rationale for advancing donor-derived γδ T cells into clinical trials for AML and other cancers, following the company's current Phase 1 trial of CAR-γδ T cells in Singapore. - The company plans to initiate clinical trials in Southeast Asia to bring novel immunotherapy options to patients with limited treatment alternatives.
- CytoMed Therapeutics successfully completed dose level 1 of its first-in-human Phase I ANGELICA trial for CTM-N2D therapy in four late-stage cancer patients. - The company's novel allogeneic CAR gamma delta T cell therapy targets NKG2DL antigens commonly present in many cancers without requiring donor-patient compatibility matching. - CTM-N2D represents a significant advancement over conventional CAR-T therapies by using donor-derived gamma delta T cells rather than patient-derived cells. - The trial is scheduled to advance to dose level 2 in the third quarter of 2025, evaluating safety and tolerability in advanced solid and hematological malignancies.
- TC Biopharm's OmnImmune is advancing through a pivotal Phase 2/3 trial for acute myeloid leukemia, representing one of the most advanced gamma delta T cell therapies globally. - The company's TCB008 candidate achieved complete molecular remission in a relapsed patient with detectable minimal residual disease after just two doses in the Phase 2 ACHIEVE trial. - More than 25 gamma delta T cell therapies are currently in clinical development worldwide, with the highest phase reaching Phase 2/3, though no therapies have achieved commercial availability as of June 2025. - The field remains predominantly focused on hematologic malignancies, with fewer programs targeting solid tumors due to complex tumor microenvironments and immune evasion mechanisms.
- CytoMed Therapeutics and SunAct Cancer Institute collaborate to evaluate allogeneic gamma delta T cells for solid tumor treatment in a Phase 2 trial. - The trial will assess the safety, tolerability, potency, and efficacy of CytoMed's cell therapy across various solid cancer types. - CytoMed will provide technical support and manufacture the cell therapy, while SunAct will offer local expertise and access to patients in India. - This collaboration aims to provide an affordable cancer treatment option and contribute to the global data pool for cancer research.
- CytoMed Therapeutics launches the ANGELICA trial, utilizing donor-derived gamma-delta T cells to target solid tumors resistant to standard treatments. - The innovative "off-the-shelf" approach aims to simplify logistics, reduce costs, and expedite treatment availability for a broader range of cancers. - CytoMed's technology leverages the unique cancer-fighting properties of gamma-delta T cells, which selectively target cancer cells while sparing healthy tissue. - The company is expanding its research into longevity and autoimmune diseases, utilizing cord blood-derived cells to address multiple medical challenges.
- CytoMed Therapeutics has begun its Phase I ANGELICA trial, evaluating CTM-ONC in patients with advanced solid tumors. - The trial utilizes CytoMed's patented donor-derived allogeneic cell therapy platform to enhance safety and efficacy. - CTM-ONC targets tumors expressing high levels of certain activating ligands, aiming to improve patient outcomes. - This first-in-human study marks a significant step for CytoMed in developing innovative cancer immunotherapies.
- CytoMed Therapeutics has received full approval for its Phase I ANGELICA trial, evaluating allogeneic CAR-T cell therapy in advanced cancers. - The ANGELICA trial uses gamma delta T cells from healthy donors, potentially improving CAR-T cell quality and reducing production costs. - The trial is co-supported by the Singapore Ministry of Health through the National Medical Research Council (NMRC) and involves collaboration with the National University Hospital (NUH). - Part 2 of the ANGELICA trial will proceed with the recruitment of patients with advanced cancers resistant to standard therapy regimens.
- The National Research Council of Canada has developed a novel CAR T-cell therapy targeting the CD22 protein on B-cell leukemia and lymphoma cells, offering hope for patients who failed previous CD19-targeted treatments. - Clinical trials for this made-in-Canada therapy are expected to begin in late 2023 across Vancouver, Ottawa, and Toronto, focusing on both pediatric and adult lymphoblastic leukemia and lymphoma patients. - The NRC's approach aims to establish domestic biomanufacturing facilities across Canada, potentially making CAR T-cell therapies more affordable and accessible compared to current imported options that come with high costs and long wait times.
